Frank Jaschinski
Planegg, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Characterization of the TLR9-Activating Potential of LNA-Modified Antisense Oligonucleotides.
Journal: Nucleic acid therapeutics
Published: July 17, 2024
Human angiotensin-converting enzyme 2-specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants.
Journal: The Journal of allergy and clinical immunology
Published: October 22, 2023
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Journal: Journal for immunotherapy of cancer
Published: April 16, 2023
Antisense Oligonucleotide Therapy Decreases IL-1β Expression and Prolongs Survival in Mutant Nlrp3 Mice.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 01, 2022
ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy.
Journal: Journal of lipid research
Published: February 14, 2022
Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing.
Journal: Nucleic acid therapeutics
Published: July 12, 2021
CHOP-ASO Ameliorates Glomerular and Tubular Damage on Top of ACE Inhibition in Diabetic Kidney Disease.
Journal: Journal of the American Society of Nephrology : JASN
Published: April 01, 2021
Using RNA-seq to Assess Off-Target Effects of Antisense Oligonucleotides in Human Cell Lines.
Journal: Molecular diagnosis & therapy
Published: November 20, 2020
Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
Journal: Molecular therapy. Nucleic acids
Published: May 25, 2020
Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Journal: Nature communications
Published: August 17, 2019
Last Updated: 09/26/2026